MDxHealth S.A. (MXDHF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MDxHealth S.A. (MXDHF) trades at $0.25 with AI Score 47/100 (Grade C). MDxHealth S. A. is a commercial-stage precision diagnostics company focused on urologic solutions, particularly prostate cancer. Market cap: $8.65M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for MXDHF: MXDHF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MXDHF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MXDHF: the 1 perspectives are evenly split.
How is this calculated? →MDxHealth S.A. (MXDHF) Healthcare & Pipeline Overview
MDxHealth S.A. specializes in precision diagnostics for urologic cancers, offering non-invasive and epigenetic tests like SelectMDx and ConfirmMDx. These solutions provide a clinical pathway for identifying prostate cancer while minimizing invasive procedures. The company operates in the US, Europe, and internationally, addressing a critical need for improved cancer diagnostics.
What Is the Investment Thesis for MXDHF?
MDxHealth operates in the growing precision diagnostics market, with a focus on urologic cancers. The company's SelectMDx and ConfirmMDx tests address a significant clinical need for improved prostate cancer diagnostics, potentially reducing unnecessary biopsies and improving patient outcomes. MDxHealth's gross margin of 59.7% indicates strong pricing power. Upcoming catalysts include expanding market penetration in the US and Europe. Key value drivers include increasing adoption of genomic testing in urology and securing reimbursement coverage from major payers. Potential risks include competition from other diagnostic companies and challenges in achieving widespread adoption of its tests. With a market cap of $8.65M and a negative P/E ratio of -5.01, MDxHealth is a high-growth, high-risk investment opportunity.
Based on FMP financials and quantitative analysis
MXDHF Key Highlights
- MDxHealth operates with a gross margin of 59.7%, indicating strong pricing power and efficient cost management in its diagnostic testing services.
- The company's focus on urologic solutions addresses a critical need for improved prostate cancer diagnostics, potentially reducing unnecessary biopsies.
- MDxHealth's SelectMDx and ConfirmMDx tests are available in the United States, the Netherlands, Belgium, Spain, Poland, Italy, the rest of the European Union, and internationally, demonstrating a global presence.
- The company employs 252 individuals, reflecting its operational scale and capacity to support its commercial activities and ongoing research and development efforts.
- MDxHealth's beta of 0.73 suggests lower volatility compared to the overall market, potentially offering a degree of stability in a portfolio.
Who Are MXDHF's Competitors?
MXDHF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CDXFF Cloud DX Inc. | $0.09 | +12.50% | $9.75M | 54 |
| DOCRF CloudMD Software & Services Inc. | $0.02 | -19.29% | $6.25M | 38 |
| HBCNF HealthBeacon plc | $0.50 | +2269.67% | $8.44M | 44 |
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MXDHF's Key Strengths?
- Proprietary diagnostic tests with clinical validation.
- Established presence in the urologic oncology market.
- Strong gross margin.
- Global presence.
What Are MXDHF's Weaknesses?
- Limited financial resources.
- Dependence on a small number of products.
- Negative profitability.
- OTC market listing.
What Could Drive MXDHF Stock Higher?
- Expansion of sales and marketing efforts in the United States to drive adoption of SelectMDx and ConfirmMDx.
- Securing additional reimbursement coverage from major payers to improve access to its diagnostic tests.
- Continued development of new diagnostic tests for urologic cancers and related conditions.
- Strategic partnerships and acquisitions to expand capabilities and market reach.
- Publication of clinical studies demonstrating the value of its diagnostic tests.
What Are the Key Risks for MXDHF?
- Financial-distress signal — its Altman Z-Score of -3.35 sits in the distress zone (elevated bankruptcy risk).
- Competition from other diagnostic companies offering similar tests.
- Regulatory changes and reimbursement pressures that could impact the adoption of its tests.
- Technological obsolescence that could render its tests outdated.
- Limited financial resources that could constrain its growth plans.
- Dependence on a small number of products, making it vulnerable to market shifts.
What Are the Growth Opportunities for MXDHF?
- Expanding Market Penetration in the United States: MDxHealth has a significant opportunity to increase its market share in the United States, the largest market for prostate cancer diagnostics. By strengthening its sales and marketing efforts, targeting key urology practices, and securing reimbursement coverage from major payers, the company can drive adoption of its SelectMDx and ConfirmMDx tests. The US prostate cancer diagnostics market is estimated to be worth billions of dollars, providing ample room for growth. Timeline: Ongoing.
- Geographic Expansion in Europe: MDxHealth can further expand its presence in Europe, leveraging its existing infrastructure and regulatory approvals. By targeting key markets such as Germany, France, and the United Kingdom, the company can capitalize on the growing demand for advanced diagnostic solutions. The European prostate cancer diagnostics market is estimated to be worth hundreds of millions of dollars, offering a significant growth opportunity. Timeline: Ongoing.
- Development of New Diagnostic Tests: MDxHealth can leverage its expertise in molecular diagnostics to develop new tests for other urologic cancers and related conditions. By expanding its product portfolio, the company can address a broader range of clinical needs and diversify its revenue streams. The market for urologic cancer diagnostics is constantly evolving, with new biomarkers and technologies emerging. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: MDxHealth can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. By collaborating with other diagnostic companies, research institutions, and healthcare providers, the company can accelerate its growth and innovation. The medical diagnostics industry is characterized by consolidation, with larger companies acquiring smaller players to gain access to new technologies and markets. Timeline: Ongoing.
- Improving Reimbursement Coverage: Securing favorable reimbursement coverage from major payers is crucial for driving adoption of MDxHealth's tests. By demonstrating the clinical and economic value of its solutions, the company can persuade payers to cover its tests, making them more accessible to patients. The reimbursement landscape for molecular diagnostics is complex and constantly evolving, requiring ongoing efforts to advocate for coverage. Timeline: Ongoing.
What Opportunities Does MXDHF Have?
- Expanding market penetration in the United States and Europe.
- Development of new diagnostic tests.
- Strategic partnerships and acquisitions.
- Improving reimbursement coverage.
What Threats Does MXDHF Face?
- Competition from other diagnostic companies.
- Regulatory changes and reimbursement pressures.
- Technological obsolescence.
- Economic downturns.
What Are MXDHF's Competitive Advantages?
- Proprietary technology and intellectual property related to its diagnostic tests.
- Established relationships with urology practices and healthcare providers.
- Reimbursement coverage from major payers.
- Brand recognition and reputation in the field of urologic oncology.
What Does MXDHF Do?
MDxHealth S.A., formerly known as OncoMethylome Sciences SA, was founded in 2003 and is headquartered in Herstal, Belgium. The company transitioned to MDxHealth SA in October 2010, marking a strategic shift towards precision diagnostics. MDxHealth focuses on developing and commercializing molecular diagnostic tests for urologic cancers, primarily prostate cancer. Their flagship products include SelectMDx and ConfirmMDx. SelectMDx is a non-invasive urine test designed to identify patients at high risk of clinically significant prostate cancer, reducing the need for unnecessary biopsies. ConfirmMDx is an epigenetic test used to assess the presence of cancer in men with a previous negative biopsy, helping to avoid repeat biopsies and improve diagnostic accuracy. MDxHealth's solutions are available in the United States, the Netherlands, Belgium, Spain, Poland, Italy, the rest of the European Union, and internationally. The company aims to provide physicians with actionable information to improve patient outcomes and reduce healthcare costs associated with prostate cancer diagnosis and management. With 252 employees, MDxHealth continues to innovate in the field of urologic oncology, striving to establish its tests as standard-of-care in the diagnostic pathway.
What Products and Services Does MXDHF Offer?
- Develops and commercializes molecular diagnostic tests for urologic cancers.
- Offers SelectMDx, a non-invasive urine test for prostate cancer risk assessment.
- Provides ConfirmMDx, an epigenetic test to detect cancer in men with prior negative biopsies.
- Aims to reduce unnecessary invasive procedures like biopsies.
- Offers solutions in the United States, Europe, and internationally.
- Focuses on improving diagnostic accuracy and patient outcomes in urology.
How Does MXDHF Make Money?
- Generates revenue through the sale of its diagnostic tests, SelectMDx and ConfirmMDx.
- Partners with urology practices and healthcare providers to offer its tests.
- Secures reimbursement coverage from insurance companies and government payers.
- Focuses on direct sales and marketing efforts to drive adoption of its tests.
What Industry Does MXDHF Operate In?
The medical diagnostics industry is experiencing rapid growth, driven by technological advancements, increasing prevalence of chronic diseases, and a growing demand for personalized medicine. The market for prostate cancer diagnostics is particularly significant, with a large aging population and rising awareness of early detection. MDxHealth competes with companies offering traditional diagnostic methods, as well as other molecular diagnostic providers. The industry is characterized by intense competition, regulatory scrutiny, and the need for continuous innovation to maintain a competitive edge. MDxHealth aims to differentiate itself through its non-invasive and epigenetic testing solutions, focusing on improving diagnostic accuracy and reducing healthcare costs.
Who Are MXDHF's Key Customers?
- Urologists and urology practices.
- Hospitals and healthcare systems.
- Patients at risk of or suspected of having prostate cancer.
- Insurance companies and government payers.
ROE 403%Key Financial Metrics
Return on equity for MDxHealth S.A. stands at 403.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -17.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -6.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.08 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -100.6%, the inverse of the P/E and a quick read on earnings relative to price.
How MDxHealth S.A. Is Valued
MDxHealth S.A. carries a market capitalization of $8.65M, placing it in the micro-cap category. Relative to its peer group, MXDHF's quantitative score of 47/100 is roughly in line with the peer average of 55/100.
F-Score 4/9Financial Health
MDxHealth S.A.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -3.35 places it in the distress zone, a signal of elevated financial risk.
MXDHF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary diagnostic tests with clinical validation.
- Established presence in the urologic oncology market.
- Strong gross margin.
- Global presence.
Bear Case
- Limited financial resources.
- Dependence on a small number of products.
- Negative profitability.
- OTC market listing.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
MXDHF Latest News
No recent news available for MXDHF.
MXDHF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MXDHF.
Price Targets
Wall Street price target analysis for MXDHF.
MXDHF MoonshotScore
What does this score mean?
The MoonshotScore rates MXDHF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Michael K. McGarrity
CEO
Michael K. McGarrity serves as the CEO of MDxHealth S.A. His background includes extensive experience in the healthcare and diagnostics industries. Prior to joining MDxHealth, McGarrity held leadership positions at various companies, where he focused on commercial strategy, market development, and product innovation. His expertise spans across sales, marketing, and operations, with a proven track record of driving growth and improving business performance. McGarrity's experience positions him well to lead MDxHealth in its mission to provide innovative diagnostic solutions for urologic cancers.
Track Record: Since assuming the role of CEO, Michael K. McGarrity has focused on expanding MDxHealth's market presence and driving adoption of its SelectMDx and ConfirmMDx tests. Under his leadership, the company has strengthened its sales and marketing efforts, secured key reimbursement agreements, and advanced its pipeline of new diagnostic products. McGarrity has also focused on improving operational efficiency and building a strong team to support the company's growth initiatives.
MXDHF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that MDxHealth S.A. may not meet the minimum financial or regulatory requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited reporting requirements and may not be subject to the same level of scrutiny as those listed on major exchanges like the NYSE or NASDAQ. This tier typically involves higher risks due to the potential for less transparency and liquidity compared to listed companies. Investors should exercise caution and conduct thorough due diligence before investing in companies on the OTC Other tier.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity compared to major exchanges.
- Less stringent reporting requirements, potentially leading to less transparency.
- Higher price volatility due to lower trading volume.
- Potential for limited regulatory oversight.
- Increased risk of fraud or manipulation.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Check for any red flags, such as pending lawsuits or regulatory investigations.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Established business operations with a history of revenue generation.
- Proprietary technology and intellectual property.
- Partnerships with reputable healthcare providers.
- Positive clinical trial results for its diagnostic tests.
- Experienced management team with relevant industry expertise.
What Investors Ask About MDxHealth S.A. (MXDHF) — Healthcare
What does MDxHealth S.A. do?
MDxHealth S.A. is a commercial-stage precision diagnostics company specializing in urologic solutions. The company develops and commercializes molecular diagnostic tests for prostate cancer, including SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic test. These tests aim to improve diagnostic accuracy, reduce unnecessary invasive procedures, and provide physicians with actionable information to improve patient outcomes. MDxHealth's solutions are available in the United States, Europe, and internationally, targeting the growing market for precision medicine in urology.
What do analysts say about MXDHF stock?
Analyst coverage of MXDHF is limited due to its OTC listing and small market capitalization. However, the company's focus on precision diagnostics and its potential to disrupt the prostate cancer diagnostic pathway have garnered some attention. Key valuation metrics include revenue growth, gross margin, and market penetration. Growth considerations include expanding market share, securing reimbursement coverage, and developing new diagnostic tests. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks.
What are the main risks for MXDHF?
The main risks for MDxHealth S.A. include competition from other diagnostic companies, regulatory changes and reimbursement pressures, technological obsolescence, limited financial resources, and dependence on a small number of products. As an OTC-listed company, MXDHF also faces liquidity challenges and potential regulatory scrutiny. Investors should carefully consider these risks before investing in MXDHF, as they could significantly impact the company's financial performance and growth prospects. The company's negative profit margin also poses a risk.
What are the key factors to evaluate for MXDHF?
MDxHealth S.A. (MXDHF) holds an AI score of 47/100 (low). Not financial advice.
How frequently does MXDHF data refresh on this page?
MXDHF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MXDHF's recent stock price performance?
MDxHealth S.A. (MXDHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary diagnostic tests with clinical validation. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MXDHF overvalued or undervalued right now?
Valuing MDxHealth S.A. (MXDHF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying MXDHF?
Before investing in MDxHealth S.A. (MXDHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide additional insights.